Lupin gains as US arm gets NDA approval for antibiotic Suprax

Pharma major Lupin is trading higher after its US arm Lupin Pharmaceuticals received the US Food and Drugs Administration approval to market and sell antibiotic Suprax capsules in 400mg strength.

FP Staff|Dec 20, 2014, 08:58:31 IST

Pharma major Lupin is trading higher on the bourses today after its US arm Lupin Pharmaceuticals received the US Food and Drugs Administration (FDA) approval to market and sell antibiotic Suprax (Cefixime) capsules in 400mg strength.

Cefixime is used to treat infections like tonsilitis and acute bronchitis among others. The approval will expand Lupin's range of Suprax dosage. It is currently available as 100 mg/5ml and 200 mg/5ml suspensions as well as 400 mg tablets.

[caption id="attachment_332672" align="alignleft" width="380" caption="Lupin shares are up 1 percent at Rs 538.20 on NSE in morning trade."][/caption]

Lupin shares are up 1 percent at Rs 538.20 on NSE in morning trade.

Commenting on the approval, Nilesh Gupta, Group President & Executive Director, Lupin Limited said "We are happy to receive this approval. The new dosage form will add to our growing SUPRAX franchise and gives health care providers and patients a new formulation to treat the indicated infections. The approval of SUPRAX capsules is one more example of our ongoing commitment to serving our customers and addressing their needs."

China has dominated Myanmar’s rare earth mines — now India eyes deal to harness country’s critical minerals

India is deepening rare earth cooperation with Myanmar as New Delhi seeks alternative sources of critical minerals dominated by China, including dysprosium and terbium used in EVs, defence systems and clean energy technologies

6 min read

JPMorgan to hire 1,000 technology professionals for India GCCs amid AI-led transformation

Wall Street banking giant to expand hiring across cloud, cybersecurity and AI data pipeline roles as it strengthens its India Global Capability Centres despite AI-driven workforce optimisation.

1 min read

BOJ seen raising interest rates by December as weak yen fuels inflation risks

Majority of economists expect Japan's central bank to deliver a 25-basis-point rate hike by year-end, with further policy tightening likely through 2027.

2 min read

'From make in India to launch from India': Skyroot COO on why Vikram-1 could change India’s space sector

Skyroot Aerospace’s successful Vikram-1 mission marks a major milestone for India’s private space sector, as the country seeks to shift from “Make in India” to “Launch from India” and compete in the global commercial satellite launch market

8 min read

Google burns cash for first time as AI spending pushes 2026 capex to $205 billion

Google parent Alphabet reported negative free cash flow of $5.9 billion in the second quarter for the first time since going public, as surging AI infrastructure spending pushed its 2026 capital expenditure forecast to as much as $205 billion